[{"id":"c1812af5-f31c-4727-996c-067f0f1f8110","acronym":"","url":"https://clinicaltrials.gov/study/NCT01483144","created_at":"2021-01-18T06:11:45.479Z","updated_at":"2024-07-02T16:36:29.390Z","phase":"Phase 3","brief_title":"Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)","source_id_and_acronym":"NCT01483144","lead_sponsor":"Cancer Prevention Pharmaceuticals, Inc.","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Flynpovi (eflornithine/sulindac)"],"overall_status":"Completed","enrollment":" Enrollment 171","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2021-06-08"}]